{"id":235194,"date":"2026-09-08T13:39:58","date_gmt":"2026-09-08T08:09:58","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=235194"},"modified":"2026-09-08T13:40:01","modified_gmt":"2026-09-08T08:10:01","slug":"is-anthem-biosciences-a-good-buy-after-q1-fy27-results-2","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/is-anthem-biosciences-a-good-buy-after-q1-fy27-results-2\/","title":{"rendered":"Is Anthem Biosciences a Good Buy After Its Q1 FY27 Results?"},"content":{"rendered":"

Anthem Biosciences share price around Rs 925. 5.0% below 52-week high of Rs 974. Q1 FY27 revenue Rs 443 crore, down 21.3% YoY. PAT Rs 120 crore, down 11.7%. PE 91x.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Anthem Biosciences’ Q1 FY27 results were mixed, with revenue at Rs 443 crore but PAT falling 12% to Rs 120 crore. The Anthem Biosciences share price near Rs 925 has not escaped this pressure, and the profit decline is the key data point investors should weigh before deciding whether Anthem Biosciences is a good buy right now.<\/p>\n<\/div>\n

The Anthem Biosciences share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Anthem Biosciences is a contract research, development and manufacturing organisation (CRDMO) for pharma and biotech clients, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.<\/p>\n

Revenue for the quarter came in at Rs 443 crore, down 21.3% year on year, while profit after tax came in at Rs 120 crore, down 11.7% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Anthem Biosciences share price from here.<\/p>\n

This piece works through the quarter’s financial highlights, the business factors behind the numbers, where the Anthem Biosciences share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n